Introduction
 [8, 9] 
Materials and methods

Human brain tissue and immunohistochemical procedures
Postmortem brain tissues containing the entorhinal cortex from seven ND cases (60-80 years of age; postmortem intervals, 4-24 hrs) and eight AD cases (67-78 years of age; postmortem intervals, 4-10 hrs) were obtained from the Kinsmen Laboratory brain bank at the University of British Columbia (UBC, Vancouver, BC, Canada). All cases of AD were confirmed by the clinical criteria for AD, as defined by the National Institute of Neurological and Communicative Disorders, and the Stroke/Alzheimer's Disease and Related Disorders Association. ND cases had no clinical or pathological history of AD. Patients with a prior history of hypertension were excluded from this study because hypertension may predispose the patient to develop abnormalities of BBB.
In this study, single/double immunohistochemical methods (visualized using 3, and nickel-ammonium sulphate as the chromogen) and double immunofluorescent staining (visualized by fluorescent secondary antibody) were applied for human tissue section staining as described below. Single immunohistochemistry was performed as described previously [10] . Free-floating sections (30 µm) 
Immunohistochemical analysis of human ND/AD tissue
The boundaries of entorhinal cortex were defined as previously described [12] . Quantitative 
Preparation and administration of A␤ peptide and fibrinogen
Amyloid-␤ peptide (A␤1-42)
Procedures followed published protocols [9, 15, 16] [20, 21] . 
Anti-Mac-1 antibody
Immunohistochemistry procedures and analysis of rat brain
The procedures follow published protocols [13, 14] Fig. 2C .
We also examined for fibrinogen association with deposits of A␤. ND brain sections showed very low levels of A␤ (upper left panel, Fig. 1C) and no evidence for any double staining of fibrinogen with A␤ (upper right panel, Fig. 1C). However, AD brain tissue demonstrated considerable areas of both A␤ deposition and fibrinogen ir (lower left and middle panels, Fig. 1C). The patterns of fibrinogen ir indicated regions where the serum protein was in proximity to amyloid plaque deposits (see magnified inset in lower right panel) and regions with no evident co-localization of markers (lower right panel).
Patterns of vascular staining (vWF ir) and BBB leakiness (IgG permeability) in AD and ND brain sections
The pattern of fibrinogen staining in parenchymal entorhinal cortical regions of AD brain tissue indicated leakiness and increased permeability of BBB. This point was further investigated by staining for IgG as a marker for integrity of the barrier [8]. A low magnification photomicrograph of entorhinal cortical IgG ir is presented for ND and AD sections (Fig. 2B). A considerably increased intensity of IgG staining was evident in AD, relative to ND, brain. The overall density of IgG, from analysis of eight AD and seven ND samples, is presented in
AD tissue demonstrated a 2.4-fold increase in IgG ir compared with ND tissue (P = 0.003).
Association of fibrinogen expression with microgliosis and astrogliosis
We have recently demonstrated activated microglia are associated with vascular remodelling and leaky BBB in A␤1-42 peptide-injected rodent brain [9] (Fig. 4, lower panel) . These patterns of immunostaining were consistent throughout entorhinal cortical regions. [20, 21] .
Fig. 4 Representative double immunohistochemical staining for microglia (HLA-DR marker) and A␤ (6F/3D marker) in the entorhinal cortex of nondemented (ND) and Alzheimer's disease (AD) tissue. Sections were incubated with HLA-DR and A␤ followed by visualization using DAB/nickel ammonium sulphate (anti-HLA-DR, dark purple colour) or DAB (anti-A␤, brown colour). Staining shows blood vessels (v) with AD tissue demonstrating close association between A␤, microglia and vessel. Scale bar represents 50 µm. Note the predominant ramified and ameboid morphologies of microglia in ND and AD tissue, respectively.
Representative staining for fibrinogen and IgG, in the absence and presence of ancrod treatment with 7 days injection of A␤1-42, are presented in Fig. 7A. Both vascular markers exhibited intense staining following A␤1-42 injection with considerable extents of ir co-localized with vessels. Ancrod treatment reduced ir levels for both markers. Quantification for the effects of ancrod intervention on the vascular proteins are presented in Fig. 7B (overall results from n = 6 animals). Ancrod was highly effective in reduction of fibrinogen ir with a decrease of 80% compared with no drug treatment of A␤1-42-injected hippocampus (P = 0.001). The corresponding reduction in IgG levels with ancrod was 52% also representing a significant decrease (P = 0.01).
We also estimated the effects of ancrod treatment on plasma fibrinogen levels from ancrod and control (saline-injected) animals. Western blot assay (see Supplementary Methods) showed controls expressed intact fibrinogen with no evidence for any fibrin degradation products (data not shown). However, ancrodtreated animals demonstrated considerable evidence for fibrin degradation products with immunoblots showing fibrin fragments with only a low level of residual fibrinogen (data not shown). On the basis of band intensities, we would estimate that fibrinogen depletion in animals receiving ancrod was in excess of 65% of total levels. This estimate is consistent with previous results, with similar administrations of ancrod, which report
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Fig. 5 Fibrinogen and microglia (OX-42) double immunofluorescent staining in A␤1-42-injected rat hippocampus. (A) In controls (7 days injection of PBS, upper panel or reverse peptide A␤42-1, second panel) low levels of fibrinogen (left column) and numbers of microglia (middle column) are evident. The right column shows merged staining. Subsequent panels show progressive time-dependent changes in fibrinogen/OX-42/ merged immunoreactivity for 1, 3 and 7-day durations of A␤1-42 injection. Scale bar represents 200 µm. (B) Double staining for A␤1-42 and fibrinogen (7 days after injection). Scale bar = 80 µm. reductions in plasma fibrinogen levels or fibrinogen-dependent processes of 60-70%
Ancrod effects on gliosis and neuronal integrity: Typical patterns of microglial (Iba-1), astrocyte (GFAP) and neuronal (NeuN) staining are shown in Fig. 8A with PBS (left panels), A␤1-42 alone (middle panels) and A␤1-42 with ancrod treatment (right panels). Markers for microgliosis (Iba-1) and astrogliosis (GFAP) showed high intensity staining in A␤1-42, but not PBS, injected brain. Ancrod treatment of A␤1-42-injected animals reduced both gliotic markers. Quantification of data (n = 6 animals) showed microgliosis significantly diminished (by 44%) in the presence of ancrod (Fig. 8B) (P = 0.006). Although astrogliosis was lower in ancrod-injected animals (by 17%), this effect did not reach significance (P = 0.308). Neuronal viability in the granule cell layer was determined by measuring NeuN ir for the three different animal groups. Representative data (lower panels, Fig 8A) show a considerable decrease in numbers of neurons in A␤1-42-injected hippocampus compared to control PBS injection. Treatment of A␤1-42-injected animals with ancrod was effective in increasing viability of neurons. Quantitative analysis (n = 6 animals) demonstrated the efficacy of ancrod treatment in providing a significant degree of neuroprotection with the numbers of dentate gyrus neurons increased by 26% compared with PBS-injected animals (Fig. 8B) (P = 0.043).
Effects of enhanced in vivo stimulation with A␤ 1-42 combined with fibrinogen and inhibition of microglial activation using anti-Mac-1
The presence of fibrinogen ir in parenchymal regions for both AD brain and in vivo following injection of A␤1-42 into the rat hippocampus, suggested the relevance in testing for the effects of combining A␤1-42 plus fibrinogen as an enhanced stimulus for microgliosis, vascular remodelling and intactness of BBB and neuronal damage. We further hypothesized that inflammatory responses mediated by activated microglia could be involved in
Fig. 6 Fibrinogen and astrocyte (GFAP) double immunofluorescent staining in A␤1-42-injected (7 days) hippocampus. GFAP immunoreactivity (ir; middle panels) was increased with A␤1-42 compared to controls (PBS and A␤42-1). Typical merged staining is shown in the right panels. Scale bar = 200 µm. The inset in the lower right panel presents a higher magnification showing negligible association of fibrinogen with GFAP ir astrocytes.
perturbations in vascular processes. Thus, we also investigated for effects of reducing microglial activation using anti-Mac-1 antibody [22] , in the presence of A␤1-42 plus fibrinogen stimulation.
Initial experiments examined the effects of combined stimulation (A␤1-42 + fibrinogen for 7 days) and use of anti-Mac-1 on microgliosis (Iba-1 marker). Representative staining shows relatively low expression of Iba-1 in controls (PBS and reverse peptide, left panels of Fig. 9A). Microgliosis was increased with A␤1-42 injection (upper middle panel) and further amplified in the presence of the combined stimuli (upper right panel). Anti-Mac-1 administration was effective in inhibiting Iba-1 ir for both A␤1-42 (lower middle panel) and for A␤1-42 plus fibrinogen (lower right panel), injections.
Quantification of data (n = 6 animals) is presented in Fig. 9B . Fig. 9C) and A␤1-42 alone (lower middle panel, Fig. 9C ).
Expression of Iba-1 was increased 45% with the combined stimulation compared with A␤1-42 alone (P = 0.002) with anti-Mac-1 effective in reducing this expression (by 24%) (P = 0.034). Administration of anti-Mac-1 also significantly inhibited Iba-1 ir with A␤1-42 injection alone (by 44%) (P = 0.005). Control injections with PBS or reverse peptide demonstrated regions of intact dentate gryrus neurons (left panels, Fig. 9C). Considerable neuronal loss accompanied A␤1-42 injection, which was further exacerbated with inclusion of fibrinogen with A␤1-42 (upper middle and right panels, Fig. 9C). Administration of anti-Mac-1 protected against neuronal loss for both combined stimuli (lower right panel,
Quantification of data (Fig. 9D) 
showed A␤1-42 plus fibrinogen injection increased neuronal loss by 45% compared to A␤1-42 alone (P = 0.006). Treatment with anti-Mac-1 increased numbers of neurons by 35% with stimuli combined and by 26% with A␤1-42 injection; these values represented significant degrees of neuroprotection with anti-Mac-1 (P = 0.004).
Intactness of BBB was also determined in these experiments using staining for IgG. Low levels of IgG activity were measured in PBS and reverse peptide controls (left panels of Fig. 10A) 
Overall (n = 6 animals), the area density of IgG was increased by 98% with A␤1-42 plus fibrinogen compared with A␤1-42 alone (Fig. 10B) (P = 0.004). IgG expression was attenuated by 38% by anti-Mac-1 in the presence of the combined stimuli (P = 0.01). The corresponding value for anti-Mac-1 inhibition of IgG with A␤1-42 injection alone was 65%. These reductions in IgG levels, induced by the inhibition of microglial activation, were significant (P = 0.006).
It staining of vWF in cerebral cortex, which was attributed to a damaged vessel [26] . Elevated levels of fibrinogen have been reported in AD, relative to ND, brain [5, 6] and in transgenic AD mice [7] with increased plasma fibrinogen reported to increase the risk of AD and vascular dementia [27] (Fig. 2B) .
Gliosis, both micro (Fig. 3A) and astro (Fig. 3B) (Fig 4) . Although microglial ir with fibrinogen, A␤ or vessels was not quantified in AD brain tissue, such associations were relatively common. The predominant ameboid morphology of AD microglia suggested cells were in activated states [24, 28] .
The findings from analysis of AD and ND tissue prompted detailed in vivo experiments using intra-hippocampal injection of A␤1-42, alone or combined with fibrinogen and pharmacological modifications of fibrinogen levels and microglial activation. (Fig. 5A) . Double staining showed areas of association of fibrinogen with proliferating microglia, which increased with duration of [29, 30] . The double staining data presented in Fig. 3 (Fig. 9D) . In both cases anti-Mac-1 provided significant neuroprotection.
Injection of A␤1-42 caused time-dependent (3-7 days) increases in expression of fibrinogen and microgliosis whereas controls (7 days injection of PBS or A␤42-1) exhibited low levels of both
We considered that if microglial reactivity underlined changes in neuronal damage, then decreasing the severity of brain insult using A␤1-42 alone (compared with A␤1-42 plus fibrinogen) and inhibiting (Fig. 10) 
